Jonna Lorenz

The highest rate of myocarditis or pericarditis after mRNA COVID-19 vaccination occurred among young men ages 18 to 24 after receiving a second dose of the Moderna vaccine.

HIV epidemics are emerging among key populations in the Middle East and North Africa, and the region ranks lowest globally in response indicators.

Frequent recurrence of Clostridioides difficile infection drives up financial burdens of the disease and underscores the need to improve access to treatment, infection prevention, and new therapies.

Most children with multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19 receive improper antimicrobial treatment, according to a recent study that highlights an urgent need to improve diagnosis and treatment of the condition.

Health care workers in Italy infected with SARS-CoV-2 were less likely to develop long COVID symptoms if they were fully vaccinated and boosted with an mRNA vaccine, a recent study found.

A computational framework for estimating vaccine effectiveness based on genetic differences of SARS-CoV-2 variants showed promising results in a new study that verified the model with clinical trial data.

The Centers for Disease Control and Prevention (CDC) is seeking more data on a possible cause of acute hepatitis in children, calling on clinicians to screen for adenovirus infections along with a broad range of possible exposures.

Patients with recurrent Clostridioides difficile infection saw improvements in fecal microbiome and bile acid after treatment with the investigational microbiota-based live biotherapeutic RBX2660.

High vaccination rates at Cornell University prevented severe disease during the Omicron surge of the COVID-19 pandemic but didn’t stop the rapid spread of the virus, even with comprehensive public health measures.

Merck’s antiviral drug molnupiravir may benefit nonhospitalized patients with mild or moderate COVID-19, according to a secondary analysis of phase 3 clinical trial data.

A recent study in the United Kingdom suggests that more research into the possible benefits of antiviral drug tecovirimat for treating monkeypox may be warranted after showing positive results in one patient.

New research in Israel offers hope that multisystem inflammatory syndrome in children—a serious complication of COVID-19—declined during the Omicron surge of the pandemic.

A new study from the CDC underscores the importance of staying up to date on COVID-19 vaccines and boosters, showing a rapid drop in vaccine effectiveness among children during the Omicron wave that increased with booster doses.

A new study in the United Kingdom provided evidence in support of a fourth dose of COVID-19 vaccines, showing a strong boost in immunity.

Phase 3 clinical trial data showed Takeda Pharmaceuticals’ antiviral drug maribavir (Livtencity) was superior to conventional antiviral treatment for clearing cytomegalovirus infections in transplant recipients.

Using monoclonal antibodies as post-exposure prophylaxis could be a cost-effective approach to battling COVID-19 in scenarios that include high transmission of susceptible variants, a new study suggests.

Immune escape for the BA.2 subvariant, or “stealth Omicron,” was not as severe as that of the original Omicron variant, a new study suggests.

The pandemic offered valuable lessons on improving the translation of evidence to practice, according to a recent survey of academic medical centers.

An analysis of readmissions after hospitalization with community-acquired pneumonia (CAP) in France found that few readmissions were avoidable, supporting criticism that the measure may lead to unfair penalties under pay-for-performance programs.

Patients scheduled for primary care appointments were more likely to get an influenza vaccine if they received a text message the night before indicating one was reserved for them, a new study shows.

Humanigen’s monoclonal antibody lenzilumab shows promise for treating COVID-19 as new variants of the disease challenge the efficacy of other therapies.

A pair of new studies in the Journal of the American Medical Association add to growing evidence that COVID-19 vaccines are safe during pregnancy, showing no increased risk for adverse outcomes among women who were vaccinated during pregnancy and their babies.

The World Health Organization updated its guidelines for the treatment of nonsevere tuberculosis in children after a study showed a four-month duration was noninferior to six months.

COVID-19 vaccines were less protective against symptomatic infection from the Omicron COVID-19 variant than the Delta variant.

The Omicron variant of SARS-CoV-2 had a secondary attack rate of 25.1% in Norwegian households compared with 19.4% for the Delta variant.

Recent booster shots of mRNA vaccines prevented severe infection, hospitalization and death during the Omicron wave of the pandemic, despite a higher rate of breakthrough infections than was seen during the Delta wave, a new study found.

Pfizer’s COVID-19 pill Paxlovid, which includes nirmatrelvir and ritonavir, reduced the risk of hospitalization and death by 89% among adults at high risk for severe disease, recently published phase 2/3 trial data show.

A recent study in Guangdong, China, confirmed vaccine effectiveness of inactivated COVID-19 vaccines against the Delta variant of COVID-19.

Investigators evaluating the risks and benefits of adding antiplatelet therapies to the usual heparin therapy for non-critically ill patients hospitalized with COVID-19 found no benefit to the approach.

Health care workers in Taiwan who were previously infected with SARS-CoV-1 showed a more robust antibody response to the AstraZeneca COVID-19 vaccine, a new study found.